XPACE-1010

XPACE-1010 is an mRNA-based therapeutic candidate being developed by Xanadu Bio for the treatment of non-small cell lung cancer (NSCLC). The drug utilizes Xanadu's proprietary PACE (Polymer for Advancement of Cell Engineering) platform, which consists of biodegradable polymer nanoparticles designed for the efficient delivery of mRNA to specific tissues. XPACE-1010 is engineered to modulate the Interleukin-23 (IL-23) pathway within the lung tissue. While the specific functional outcome—whether it involves the expression of IL-23 to stimulate an anti-tumor immune response or the delivery of mRNA encoding a neutralizing agent—is not explicitly detailed in public pipeline summaries, the program is optimized for lung-specific activity. As of early 2025, XPACE-1010 is in the preclinical and IND-enabling stages of development.